• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    HBM Holdings (SEHK:2142) Wins Batoclimab Approval As Fair Value Stays In Focus

    Simply Wall St·10/25/2026 08:24:23
    Listen to the news

    HBM Holdings (SEHK:2142) is in focus after China’s drug regulator approved batoclimab, a subcutaneous biologic for generalized myasthenia gravis, backed by a pivotal Phase 3 study showing clinically meaningful patient improvements.

    HBM Holdings has had a choppy year in the market, with the 30-day share price return down 25.96% and the year-to-date share price return down 15.23%. However, the 3-year total shareholder return is very large at around 7x, so momentum has cooled recently even as long term holders still sit on substantial gains.

    Scan beyond HBM Holdings and surface other antibody and biotech players with potential catalysts using our curated 613 high quality undiscovered gems in the same high-risk, high-reward corner of the market.

    HBM Holdings now trades well below its recent highs after a sharp pullback, coming immediately after a major drug approval. Do you lean into the weakness or wait for the valuation section to highlight a clearer entry window?

    Most Popular Narrative: 57% Undervalued

    HBM Holdings closed at HK$10.24 while the most followed narrative anchors fair value around HK$24.02. The current pullback sits well below that framework and shifts attention to how durable the pipeline and earnings story really is.

    Ongoing build out of Harbour BioMed’s platform based model, with three defined growth engines in assets, technology and partnerships, points to additional collaboration and out licensing income that could support revenue and earnings.

    See why 1 investors see HBM Holdings as 57% undervalued.

    Result: Fair Value of HK$24.02 (UNDERVALUED)

    Still, this hinges on HBM Holdings keeping key respiratory and oncology programs on track, as well as collaboration or licensing deals arriving in a timely way.

    Find out about the key risks to this HBM Holdings narrative.

    Next Steps

    This mix of enthusiasm and caution around HBM Holdings leaves the verdict open. Move quickly, test the assumptions against the numbers, and then weigh both sides through 4 key rewards and 1 important warning sign.

    Looking for more HBM Holdings investment ideas?

    If you want to pressure test your view on HBM Holdings, branch out into similar opportunities and compare risk, quality, and income profiles side by side.